Literature DB >> 1974402

Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis.

G Ciprandi1, P M Cerqueti, S Sacca, P Cilli, G W Canonica.   

Abstract

Thirty patients with allergic conjunctivitis, caused by Parietaria or grass pollens, participated in a double-blind parallel study comparing levocabastine to cromolyn sodium, both given as eye drops. Symptom and sign scores were recorded during a 4-week period. The patients received only these drugs during the time of observation. The evaluation of the clinical signs and symptoms by the clinicians and by the patients revealed a significant improvement of conjunctivitis in all patients. The intergroup comparison was equal in the two groups treated respectively with levocabastine and cromolyn. Therefore, levocabastine and cromolyn are effective in the treatment of pollen-induced allergic conjunctivitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974402

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  7 in total

1.  Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries.

Authors:  C G Pinto; A Lafuma; F Fagnani; M J Nuijten; G Berdeaux
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Evidence based general practice: a retrospective study of interventions in one training practice.

Authors:  P Gill; A C Dowell; R D Neal; N Smith; P Heywood; A E Wilson
Journal:  BMJ       Date:  1996-03-30

Review 3.  The antihistamines of the nineties.

Authors:  M M Janssens; P H Howarth
Journal:  Clin Rev Allergy       Date:  1993

Review 4.  Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis.

Authors:  K L Dechant; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 5.  Ocular allergy guidelines: a practical treatment algorithm.

Authors:  Leonard Bielory
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 7.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.